These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 29290258)

  • 1. Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Isaka M; Kojima H; Takahashi S; Omae K; Ohde Y
    Lung Cancer; 2018 Jan; 115():28-33. PubMed ID: 29290258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.
    Riquet M; Assouad J; Bagan P; Foucault C; Le Pimpec Barthes F; Dujon A; Danel C
    Ann Thorac Surg; 2005 Jan; 79(1):225-33. PubMed ID: 15620948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors influencing survival and recurrence and potential significance of postoperative radiotherapy and adjuvant chemotherapy for stage ⅢA-N2 non-small cell lung cancer].
    Han W; Song YZ; He M; Li J; Zhang R; Qiao XY
    Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):861-867. PubMed ID: 27998447
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement.
    Sawyer TE; Bonner JA; Gould PM; Foote RL; Deschamps C; Trastek VF; Pairolero PC; Allen MS; Shaw EG; Marks RS; Frytak S; Lange CM; Li H
    Cancer; 1997 Oct; 80(8):1399-408. PubMed ID: 9338463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics and lymph node metastasis pathway of non-small-cell lung cancer located in the left lingular division.
    Shien K; Toyooka S; Soh J; Okami J; Higashiyama M; Kadota Y; Maeda H; Hayama M; Chida M; Funaki S; Okumura M; Miyoshi S
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):791-6. PubMed ID: 25805399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease.
    Razi SS; Nguyen D; Villamizar N
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2469-2483.e4. PubMed ID: 31928821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.
    Taylor MD; LaPar DJ; Thomas CJ; Persinger M; Stelow EB; Kozower BD; Lau CL; Jones DR
    Ann Thorac Surg; 2013 Oct; 96(4):1163-1170. PubMed ID: 23998409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of skip N2 metastases in stage IIIA non-small cell lung cancer].
    Liu K; Chen HL; You QS; Huang JF; Wang H
    Ai Zheng; 2009 Jul; 28(7):725-9. PubMed ID: 19624899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of metastatic N1 lymph nodes in completely resected non-small-cell lung cancer.
    Park S; Cho S; Yum SW; Kim K; Jheon S
    Interact Cardiovasc Thorac Surg; 2015 Nov; 21(5):624-9. PubMed ID: 26242319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival.
    Varlotto JM; Yao AN; DeCamp MM; Ramakrishna S; Recht A; Flickinger J; Andrei A; Reed MF; Toth JW; Fizgerald TJ; Higgins K; Zheng X; Shelkey J; Medford-Davis LN; Belani C; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):765-73. PubMed ID: 25752390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surgical therapeutic strategy for non-small cell lung cancer with (N2) mediastinal lymph node metastasis].
    Huang GJ; Fang DK; Cheng GY; Zhang DC
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):62-4. PubMed ID: 16737625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis of 220 patients with completely resected stage-II non-small cell lung cancer.
    Dai Y; Su XD; Long H; Lin P; Fu JH; Zhang LJ; Wang X; Wen ZS; Zhu ZH; Zhang X; Rong TH
    Chin J Cancer; 2010 May; 29(5):538-44. PubMed ID: 20426905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer.
    Lardinois D; Suter H; Hakki H; Rousson V; Betticher D; Ris HB
    Ann Thorac Surg; 2005 Jul; 80(1):268-74; discussion 274-5. PubMed ID: 15975380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonectomy vs lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival?
    Luzzi L; Voltolini L; Campione A; Paladini P; Ghiribelli C; Di Bisceglie M; Gotti G
    J Cardiovasc Surg (Torino); 2003 Feb; 44(1):119-23. PubMed ID: 12627083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.
    Darling GE; Allen MS; Decker PA; Ballman K; Malthaner RA; Inculet RI; Jones DR; McKenna RJ; Landreneau RJ; Rusch VW; Putnam JB
    J Thorac Cardiovasc Surg; 2011 Mar; 141(3):662-70. PubMed ID: 21335122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.